Alexandra SchÃ¤fer

List of Publications by Year
in descending order

49 papers	12,578 citations	109321 35 h-index	197818 49 g-index
70 all docs	70 docs citations	70 times ranked	20820 citing authors

#	Article	IF	Citations
1	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 2020, 11, 222.	12.8	1,376
2	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 2020, 182, 429-446.e14.	28.9	1,257
3	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	27.8	1,153
4	Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584, 443-449.	27.8	956
5	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine, 2020, 12, .	12.4	886
6	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468.	12.6	808
7	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020, 586, 560-566.	27.8	527
8	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 2020, 183, 1070-1085.e12.	28.9	472
9	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell, 2020, 183, 169-184.e13.	28.9	446
10	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	28.9	420
11	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Reports, 2020, 32, 107940.	6.4	412
12	Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. MBio, 2015, 6, e00638-15.	4.1	390
13	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, 591, 451-457.	27.8	320
14	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	8.5	283
15	Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses. MBio, 2014, 5, e01174-14.	4.1	246
16	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
17	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science, 2021, 373, 991-998.	12.6	144
18	MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1012-E1021.	7.1	142

#	Article	IF	Citations
19	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	28.9	131
20	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature, 2021, 599, 465-470.	27.8	129
21	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell, 2020, 183, 429-441.e16.	28.9	100
22	Epigenetic Landscape during Coronavirus Infection. Pathogens, 2017, 6, 8.	2.8	96
23	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
24	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29832-29838.	7.1	81
25	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	6.1	77
26	Allelic Variation in the Toll-Like Receptor Adaptor ProteinTicam2Contributes to SARS-Coronavirus Pathogenesis in Mice. G3: Genes, Genomes, Genetics, 2017, 7, 1653-1663.	1.8	75
27	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	6.4	64
28	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	4.4	61
29	The Role of the Blood-Brain Barrier during Venezuelan Equine Encephalitis Virus Infection. Journal of Virology, 2011, 85, 10682-10690.	3.4	59
30	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	14.3	59
31	The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. Virology Journal, 2014, 11, 209.	3.4	58
32	The effect of inhibition of PP1 and TNFÎ± signaling on pathogenesis of SARS coronavirus. BMC Systems Biology, 2016, 10, 93.	3.0	58
33	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2, 100313.	6.5	56
34	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	12.4	55
35	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Science Translational Medicine, 2022, 14, eabm3410.	12.4	49
36	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	46

#	Article	IF	Citations
37	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	14.5	39
38	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Reports, 2021, 36, 109450.	6.4	38
39	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2â€“specific monoclonal antibody CR3022. JCI Insight, 2021, 6, .	5.0	34
40	Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. Journal of Virology, 2018, 92, .	3.4	33
41	Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. Cell Reports, 2020, 31, 107587.	6.4	31
42	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathogens, 2021, 17, e1009287.	4.7	22
43	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226.	11.9	22
44	SARS-Like Coronavirus WIV1-CoV Does Not Replicate in Egyptian Fruit Bats (Rousettus aegyptiacus). Viruses, 2018, 10, 727.	3.3	21
45	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. SSRN Electronic Journal, 0, , .	0.4	15
46	Systems approaches to coronavirus pathogenesis. Current Opinion in Virology, 2014, 6, 61-69.	5.4	12
47	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	3.4	12
48	A Multitrait Locus Regulates Sarbecovirus Pathogenesis. MBio, 2022, 13, .	4.1	11
49	Immune predictors of mortality following RNA virus infection. Journal of Infectious Diseases, 2020, 221, 882-889.	4.0	10